
    
      The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to
      treat people who have Crohn's disease. This study will look at mucosal healing in people who
      take vedolizumab.

      The study will enroll approximately 100 patients and will be conducted in 2 Parts. Part A
      will consist of a 26-week treatment period and all participants will receive vedolizumab 300
      mg intravenously (IV) on Day 1 and at Weeks 2, 6, 14 and 22. Part B will consist of a 26-week
      extension treatment period and all participants will receive vedolizumab 300 mg IV at Weeks
      30, 38, and 46.

      This multi-center trial will be conducted worldwide. The overall time to participate in this
      study is approximately 70 weeks for Parts A, B and 18-Week Follow-up combined. Participants
      will make multiple visits to the clinic. All participants included in the study will also
      have a 6 month safety follow-up telephone call following his/her last dose of study drug.
    
  